Provided by Tiger Trade Technology Pte. Ltd.

TYK MEDICINES-B

4.285
+0.1453.50%
Volume:167.50K
Turnover:720.71K
Market Cap:1.63B
PE:-4.58
High:4.550
Open:4.140
Low:4.140
Close:4.140
52wk High:18.500
52wk Low:2.410
Shares:380.07M
HK Float Shares:375.46M
Volume Ratio:0.44
T/O Rate:0.04%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.936
ROE:-70.66%
ROA:-28.19%
PB:5.33
PE(LYR):-4.58
PS:13009.12

Loading ...

TYK Medicines Chairman Wu Yusheng Buys 635,000 H Shares for Hk$2.09 Million

Reuters
·
Sep 10

TYK MEDICINES-B: Yusheng Wu Acquires Shares, Long Position Rises to 32.59%

HK Disclosure
·
Sep 10

TYK MEDICINES-B: Yusheng Wu Acquires Shares, Long Position Rises to 32.57%

HK Disclosure
·
Sep 09

TYK Medicines' Chairman Boosts Stake; Shares Down 8%

MT Newswires Live
·
Sep 09

TYK Medicines-B Chairman, President and CEO Wu Yusheng Plans Share Purchase

Stock News
·
Sep 08

Tyk Medicines - Increase in Shareholding by CEO Will not Exceed HK$2 Mln

THOMSON REUTERS
·
Sep 08

Tyk Medicines - Chairman, CEO DR. Wu Yusheng Purchases Shares of Tyk Medicines on Open Market

THOMSON REUTERS
·
Sep 08

Insider Sellers Might Regret Selling TYK Medicines Shares at a Lower Price Than Current Market Value

Simply Wall St.
·
Sep 01

Regulatory Approval Granted to TY-9591, a Novel Targeted Therapy for EGFR-Mutant Lung Cancer With Brain Metastases

Stock News
·
Aug 28

Shares of TYK Medicines-B Jump Nearly 15% in Morning Trading as Its Innovative Drug TY-9591 Receives Conditional Market Approval

Deep News
·
Aug 28

TYK MEDICINES-B Secures Conditional NMPA Approval for Its Novel EGFR-TKI Therapy

Stock News
·
Aug 27

TYK Medicines Says China Regulator Grants Conditional Approval for TY-9591 Lung Cancer Drug

Reuters
·
Aug 27

Tyk Medicines - Asandeutertinib Mesylate Tablets (Ty-9591) Obtains Conditional Marketing Approval from Nmpa

THOMSON REUTERS
·
Aug 27

TYK Medicines Extends Long-Stop Date for 63.22 Million H-Share Placement to 20 September 2026

Bulletin Express
·
Aug 20

Hong Kong Stock Spotlight | TYK Medicines-B (02410) Climbs Over 6% in Morning Trade as Half-Year Loss Narrows Sharply and TY-9591 Commercialization Ramps Up

Stock News
·
Aug 18

TYK Medicines-B Narrows First-Half Loss Significantly as Manufacturing and Commercial Expansion Moves Forward

Stock News
·
Aug 17

TYK Medicines outlines 2026 board reshuffle, schedules vote on seven director re-elections

Bulletin Express
·
Aug 17

TYK Medicines FY26 H1 Comprehensive Loss Narrows 76.4% to RMB 26.88 Million

Reuters
·
Aug 17

TYK Medicines Files List of Directors, Board Committee Memberships and Disclosure-Responsible Management

Reuters
·
Aug 17

TYK Medicines Non-Executive Director Jiang Mingyu Resigns, Wu Yusheng Named Authorized Representative

Reuters
·
Aug 17